ELIZABETH THOMPSON: Open Payments
NPI 1588015366 · OGDEN, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,027 in 60 payments from 22 companies in 2025. Trend: 2023 $747 · 2024 $1,219 · 2025 $1,027
Food & beverage: $1,027
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $226 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $129 |
| Novo Nordisk Inc | 4 | $83 |
| Vifor Pharma, Inc. | 4 | $74 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| Lilly USA, LLC | 3 | $49 |
| AstraZeneca Pharmaceuticals LP | 3 | $44 |
| SANOFI-AVENTIS U.S. LLC | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Dexcom, Inc. | 2 | $35 |
Products named: VRAYLAR, CAPLYTA, Veltassa, QULIPTA, Auvelity, MOUNJARO, TZIELD, REXULTI.
Industry payments across UT — which companies pay providers there.
